Wearable Activity Tracking to Curb Hospitalizations
Part of paid clinical trials in San Francisco, California.
- Sponsor
- University of California, San Francisco
- Study ID
- NCT06587100
- Status
- Recruiting
Conditions
- Hematopoietic Neoplasm
- Lymphatic System Neoplasm
- Malignant Solid Neoplasm
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Fitbit — DEVICEParticipants will wear Fitbit device
- Apple HealthKit-based devices — DEVICEParticipants will wear personal device and share data with study team.
Study Details
This study is being done to collect patient generated health data to predict the risk of patients needing emergency department visits or hospitalization before, during. and after receiving radiation therapy.
Key Dates
- Start date
- Apr 7, 2025
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 260 participants (estimated)
Arms
- Arm: Observational Group I: Fitbit onlyParticipants receive Fitbit device while undergoing non-interventional, standard of care, radiation therapy.
- Arm: Observational Group II: Fitbit + Apple HealthKitParticipants receive Fitbit device and will utilize personal Apple HealthKit-based devices (iPhone, Apple Watch, etc.) to concurrently contribute Apple HealthKit-based data while undergoing non-interventional, standard of care, radiation therapy.
Primary Outcome Measure
Area under the receiver operating characteristic curve (AUC-ROC) of the step count model [ Time Frame: Up to 3 years ]
Central Contacts
- Imani Dunn877-827-3222
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94143 | Julian Hong, MD, MS (PRINCIPAL_INVESTIGATOR) |
Find similar trials in San Francisco, CA
By research site
Related Studies
- Project: Every Child for Younger Patients With CancerRecruiting · Children's Oncology Group · Birmingham, Alabama
- Collection and Storage of Tissue and Blood Samples From Patients With CancerRecruiting · National Cancer Institute LAO · Birmingham, Alabama
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid TumorsRecruiting · SWOG Cancer Research Network · Anchorage, Alaska